



## **Algernon Pharmaceuticals Inc.**

**Symbol:** TSX.V: AGN

**Market Cap:** 33.5M

**Sector:** Healthcare

**Purpose:** Raise Awareness / Open Market Buying

Algernon is a drug repurposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow-release formulation.

### **Investor Bullet Points**

- Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
- Algernon has 2 Phase 2 clinical trials in progress for idiopathic pulmonary fibrosis and chronic cough as well as COVID-19.

### **Christopher Moreau, CEO**

Mr. Moreau is a seasoned business professional in the life sciences sector with a strong background in biotechnology research, business development and a deep expertise in the capital markets. He also has over 30 years of senior management experience in private & publicly traded company environments.